Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Carroll

Showing results (551-560 of 574) with videos related to

Pageof 58
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 8, 2014
In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotidesAmber L Southwell, Niels H Skotte, Holly B Kordasiewicz, et al.
Plos One|September 11, 2014
Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patientsNiels H Skotte, Amber L Southwell, Michael E Østergaard, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editingRicardo Mouro Pinto, Ryan Murtha, António Azevedo, et al.
Molecular Therapy. Nucleic Acids|February 2, 2026
Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA modelVelvet L Smith, Bereket Z Gidi, Robert M Bragg, et al.
Journal of Parkinson'S Disease|February 20, 2025
Improving recruitment and retention of people with Parkinson's disease to clinical studies: A scoping reviewRebecca Petty, Veena Agarwal, Jennifer Allison, et al.
Nature Genetics|January 22, 2025
In vivo CRISPR-Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington's diseaseRicardo Mouro Pinto, Ryan Murtha, António Azevedo, et al.
Communications Biology|December 9, 2021
Huntingtin structure is orchestrated by HAP40 and shows a polyglutamine expansion-specific interaction with exon 1Rachel J Harding, Justin C Deme, Johannes F Hevler, et al.
Neurobiology of Aging|September 19, 2016
Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's diseaseS J Lubbe, V Escott-Price, A Brice, et al.
BMJ Neurology Open|July 6, 2026
Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital dataTimothee Aubourg, Katarina M Gunter, Christine Lo, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 23, 2023
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease TrialsCristina Gonzalez-Robles, Michèle Bartlett, Matthew Burnell, et al.
Pageof 58

Showing results (551-560 of 574) with videos related to

Sort By:
Pageof 58
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 8, 2014
In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotidesAmber L Southwell, Niels H Skotte, Holly B Kordasiewicz, et al.
Plos One|September 11, 2014
Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patientsNiels H Skotte, Amber L Southwell, Michael E Østergaard, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editingRicardo Mouro Pinto, Ryan Murtha, António Azevedo, et al.
Molecular Therapy. Nucleic Acids|February 2, 2026
Atrophin-1 antisense oligonucleotide provides robust protection from pathology in a fully humanized DRPLA modelVelvet L Smith, Bereket Z Gidi, Robert M Bragg, et al.
Journal of Parkinson'S Disease|February 20, 2025
Improving recruitment and retention of people with Parkinson's disease to clinical studies: A scoping reviewRebecca Petty, Veena Agarwal, Jennifer Allison, et al.
Nature Genetics|January 22, 2025
In vivo CRISPR-Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington's diseaseRicardo Mouro Pinto, Ryan Murtha, António Azevedo, et al.
Communications Biology|December 9, 2021
Huntingtin structure is orchestrated by HAP40 and shows a polyglutamine expansion-specific interaction with exon 1Rachel J Harding, Justin C Deme, Johannes F Hevler, et al.
Neurobiology of Aging|September 19, 2016
Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's diseaseS J Lubbe, V Escott-Price, A Brice, et al.
BMJ Neurology Open|July 6, 2026
Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital dataTimothee Aubourg, Katarina M Gunter, Christine Lo, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 23, 2023
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease TrialsCristina Gonzalez-Robles, Michèle Bartlett, Matthew Burnell, et al.
Pageof 58